Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Selpercatinib

FDA-approved product (capsule, oral), marketed as Retevmo.

Registered studies
42
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Selpercatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Medullary thyroid gland carcinoma
  • Neoplasm
  • Non-small cell lung carcinoma
  • Papillary thyroid carcinoma
  • Thyroid cancer
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

42registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Selpercatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Selpercatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India

    NCT07822880 · start 2026-11

    Registered record
    Registry ID
    NCT07822880
    Conditions
    Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung
    Interventions
    Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Neoplasms; Carcinoma, Non-Small-Cell Lung
    InterventionSelpercatinib
    PhasePhase 4
    Registry statusNot yet recruiting

  • Molecularly Tailored Therapy in Advanced Pancreatic Cancer

    NCT07802418 · start 2026-10

    Registered record
    Registry ID
    NCT07802418
    Conditions
    Pancreatic Cancer
    Interventions
    Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy; Arm 3: Standard-of-Care Observational Cohort
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2032-06
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionArm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy; Arm 3: Standard-of-Care Observational Cohort
    PhasePhase 2
    Registry statusNot yet recruiting

  • Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations

    NCT07829744 · start 2026-09-20

    Registered record
    Registry ID
    NCT07829744
    Conditions
    Lung Cancer (NSCLC)
    Interventions
    Surgical Resection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-20
    Completion
    2030-06-30
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer (NSCLC)
    InterventionSurgical Resection
    PhasePhase 2
    Registry statusNot yet recruiting

  • Feasibility Study for Repurposing RET Inhibitors

    NCT07146893 · start 2026-02-26

    Registered record
    Registry ID
    NCT07146893
    Conditions
    Cachexia-Anorexia Syndrome
    Interventions
    Selpercatinib; Strength Assessment
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-02-26
    Completion
    2028-02-23
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCachexia-Anorexia Syndrome
    InterventionSelpercatinib; Strength Assessment
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

    NCT07419932 · start 2025-12-23

    Registered record
    Registry ID
    NCT07419932
    Conditions
    Thyroid Cancer; Thyroid Neoplasms
    Interventions
    Multitarget Tyrosine Kinase Inhibitors; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; RET Inhibitor; PD(L)-1 inhibitor; Biopsy; Surgery; Surgery
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-12-23
    Completion
    2029-06-30
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Cancer; Thyroid Neoplasms
    InterventionMultitarget Tyrosine Kinase Inhibitors; BRAF inhibitor dabrafenib and MEK inhibitor trametinib; RET Inhibitor; PD(L)-1 inhibitor +3 more
    PhaseNot recorded
    Registry statusRecruiting

  • Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

    NCT07010393 · start 2025-07-01

    Registered record
    Registry ID
    NCT07010393
    Conditions
    Thyroid Neoplasms
    Interventions
    Dabrafenib; Trametinib; Selpercatinib; Pralsetinib; Lenvatinib; Larotrectinib; Anlotinib; Pembrolizumab; Sintilimab; Cabozantinib; Bemosuzumab; Conversion Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-07-01
    Completion
    2028-12-31
    Enrolment
    335

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Neoplasms
    InterventionDabrafenib; Trametinib; Selpercatinib; Pralsetinib +8 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

    NCT06532149 · start 2024-08-05

    Registered record
    Registry ID
    NCT06532149
    Conditions
    NSCLC Stage IV; Sex Disorder; Hypogonadism, Male; Erectile Dysfunction
    Interventions
    Alectinib; Brigatinib; Lorlatinib 100 mg; Osimertinib; Sotorasib; Dabrafenib; Trametinib; Selpercatinib; Pembrolizumab; Cemiplimab; Nivolumab; Carboplatin; Pemetrexed; Paclitaxel
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-08-05
    Completion
    2026-09-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC Stage IV; Sex Disorder; Hypogonadism, Male; Erectile Dysfunction
    InterventionAlectinib; Brigatinib; Lorlatinib 100 mg; Osimertinib +10 more
    PhaseNot recorded
    Registry statusRecruiting

  • Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

    NCT06458036 · start 2024-07-29

    Registered record
    Registry ID
    NCT06458036
    Conditions
    Differentiated Thyroid Cancer; Pediatric Cancer; Cancer; Cancer, Thyroid
    Interventions
    Selpercatinib Monotherapy; 131I Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-07-29
    Completion
    2031-11-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDifferentiated Thyroid Cancer; Pediatric Cancer; Cancer; Cancer, Thyroid
    InterventionSelpercatinib Monotherapy; 131I Therapy
    PhasePhase 2
    Registry statusRecruiting

  • Selpercatinib and Body Composition

    NCT07543887 · start 2024-04-12

    Registered record
    Registry ID
    NCT07543887
    Conditions
    Thyroid Cancer
    Interventions
    observation in patient under treatment; Selpercatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-04-12
    Completion
    2026-04-04
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Cancer
    Interventionobservation in patient under treatment; Selpercatinib
    PhaseNot recorded
    Registry statusCompleted

  • A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants

    NCT05906836 · start 2023-07-27

    Registered record
    Registry ID
    NCT05906836
    Conditions
    Healthy
    Interventions
    Rosuvastatin; Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-07-27
    Completion
    2023-10-31
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRosuvastatin; Selpercatinib
    PhasePhase 1
    Registry statusCompleted

  • Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

    NCT05668962 · start 2023-03-01

    Registered record
    Registry ID
    NCT05668962
    Conditions
    Thyroid Cancer; Thyroid Carcinoma; Metastatic Thyroid Cancer; Follicular Thyroid Cancer; Unresectable Thyroid Gland Carcinoma; Papillary Thyroid Cancer
    Interventions
    Selpercatinib; Sodium Iodine I-131; rhTSH
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-03-01
    Completion
    2026-01-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Cancer; Thyroid Carcinoma; Metastatic Thyroid Cancer; Follicular Thyroid Cancer +2 more
    InterventionSelpercatinib; Sodium Iodine I-131; rhTSH
    PhasePhase 2
    Registry statusRecruiting

  • Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

    NCT05364645 · start 2022-07-25

    Registered record
    Registry ID
    NCT05364645
    Conditions
    Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Carboplatin; Pemetrexed; Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2022-07-25
    Completion
    2029-05-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8 +1 more
    InterventionCarboplatin; Pemetrexed; Selpercatinib
    PhasePhase 2
    Registry statusWithdrawn

  • A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants

    NCT05324124 · start 2022-04-19

    Registered record
    Registry ID
    NCT05324124
    Conditions
    Healthy
    Interventions
    Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-04-19
    Completion
    2022-06-22
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSelpercatinib
    PhasePhase 1
    Registry statusCompleted

  • A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

    NCT04819100 · start 2021-12-20

    Registered record
    Registry ID
    NCT04819100
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Selpercatinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-12-20
    Completion
    2028-05
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionSelpercatinib; Placebo
    PhasePhase 3
    Registry statusActive not recruiting

  • A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

    NCT05136404 · start 2021-12-03

    Registered record
    Registry ID
    NCT05136404
    Conditions
    Healthy
    Interventions
    Selpercatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-12-03
    Completion
    2022-03-14
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionSelpercatinib
    PhasePhase 1
    Registry statusCompleted